Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
NCT ID: NCT01215357
Last Updated: 2024-05-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
34 participants
INTERVENTIONAL
2010-10-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acamprosate in the Treatment of Pathological Gambling
NCT00571103
Probenecid as Medication for Alcohol Use Disorder (PROB)
NCT04218357
Investigation of Naltrexone for Pathological Gambling
NCT01057862
Reducing Inappropriate Medication Use for BPSD
NCT06040502
Gabapentin Treatment of Cannabis Dependence
NCT00974376
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ecopipam
Ecopipam is a selective antagonist of one the classes of dopamine receptor.
Ecopipam
50mg tablets
Placebo
Placebo given first week of the study.
Ecopipam
50mg tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ecopipam
50mg tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must have at least 2 episodes of gambling behavior within the previous 2 weeks before screening
* Subject must have gambling urges of at least moderate intensity
Exclusion Criteria
* Subjects with major depressive episode within the last 2 years
* Subjects with a history of attempted suicide
* Subjects with first degree relative with major depressive episode that resulted in hospitalization, attempted or completed suicide
* Subjects with a history of epilepsy or seizures
* Subjects with a myocardial infarction (heart attack) with in the last 6 months
* Subjects with a lifetime history of bipolar disorder, dementia, schizophrenia, or any psychotic disorder
* Subjects with current of recent DSM-IV diagnosis of substance abuse or dependence (with the exception of nicotine)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Psyadon Pharma
INDUSTRY
Emalex Biosciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jon Grant, MD
Role: PRINCIPAL_INVESTIGATOR
Univ. of Minnesota
Donald Black, MD
Role: PRINCIPAL_INVESTIGATOR
Iowa University
Timothy Fong, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Marc Potenza, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Los Angeles
Los Angeles, California, United States
Yale University
New Haven, Connecticut, United States
Carver College of Medicine, University of Iowa
Iowa City, Iowa, United States
University of Minnesota School of Medicine
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grant JE, Odlaug BL, Black DW, Fong T, Davtian M, Chipkin R, Kim SW. A single-blind study of 'as-needed' ecopipam for gambling disorder. Ann Clin Psychiatry. 2014 Aug;26(3):179-86.
Related Links
Access external resources that provide additional context or updates about the study.
Psyadon Pharmaceutical's Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSY201
Identifier Type: -
Identifier Source: org_study_id
NCT01198951
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.